Non-muscle Invasive Bladder Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
345 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5934287

The global non-muscle invasive bladder cancer therapeutics market reached a valuation of US$2.8 billion in 2024. The market is forecasted to progress to reach US$9.2 billion by the end of 2031.

Factors Driving the Non-Muscle Invasive Bladder Cancer Therapeutics Market

The non-muscle invasive bladder cancer (NMIBC) therapeutics market is witnessing significant growth driven by advancements in medical technology and increased research and development spending. With the development of innovative treatments such as gene therapy, targeted therapies, and immunotherapy, patients with NMIBC now have access to a wider range of therapies, leading to improved management of the disease.

Contributing Factors to High Demand for NMIBC Therapies

The rising prevalence of bladder cancer globally, coupled with a growing demand for minimally invasive procedures, is driving market growth. Advancements in immunotherapy, chemotherapy, and technology for detection and treatment are improving patient outcomes, further fueling market expansion. Additionally, increasing public awareness of bladder cancer and the importance of early detection are expected to contribute to market growth in the coming years.

Challenges Hindering Market Growth

Challenges such as high treatment costs, unfavorable side effects of some medications, and limited access to effective treatments in underdeveloped regions are hindering market growth. Additionally, the strong probability of bladder cancer recurrence and competition among multiple treatment options pose significant challenges. However, continued research and development efforts are addressing these challenges and driving innovation in NMIBC therapies.

Country-wise Insights

United States: Technologically advanced diagnostic and therapeutic methods, coupled with favorable reimbursement practices, are driving significant demand for NMIBC therapies in the U.S. The rise in bladder cancer cases and ongoing research by pharmaceutical companies further contribute to market expansion.
China: Rising healthcare costs and an aging population are driving demand for NMIBC therapies in China. Government policies supporting healthcare development and increasing public awareness are expected to further boost market growth.
Germany: Growing public awareness of early cancer diagnosis and treatment, along with advancements in medical technology, are fueling market expansion in Germany. The acceptance of less invasive techniques and increased research efforts are additional drivers of growth.

Category-wise Insights

Grade-based NMIBC with Higher Revenue Generation: The market is witnessing substantial growth due to the high incidence rate of low-grade bladder cancer. Early detection and treatment of low-grade bladder cancer are essential, driving demand for NMIBC therapies targeting this grade.
Extensively Used Drug Type: Chemotherapy remains a crucial part of NMIBC management, contributing to market expansion. Continuous research into more potent chemotherapy medications is expected to further drive market growth.

Competitive Analysis

The NMIBC therapeutics market is highly competitive, with companies focusing on expanding their reach in emerging markets and maintaining relationships with existing distributors. Strategies such as mergers, acquisitions, and partnerships with key players are employed to strengthen market presence and drive innovation.

Pfizer Inc.
Merck KGaA
AstraZeneca PLC
Roche Holding AG (Genentech)
Astellas Pharma Inc.
J&J (Janssen Biotech)
Cipla Inc.
Amneal Pharma
Bristol Myers Squibb Co.
Dr. Reddy’s Laboratories, Inc.
Gilead Sciences Inc.
Endo Pharma
UroGen Pharma, Inc.
Teva Pharmaceuticals (Actavis)
Hikma Pharmaceuticals
Incyte

Key Segments of Non-muscle Invasive Bladder Cancer Therapeutics Industry

Cancer Grade:

Low-grade Bladder Cancer
High-grade Bladder Cancer

Drug Type:

Immunotherapy
Bacillus Calmette-Guerin
Avelumab
Nivolumab
Pembrolizumab
Others
Chemotherapy
Mitomycin C
Docetaxel
Paclitaxel
Cisplatin
Others
Targeted Therapy
Erdafitinib
Enfortumab Vedotin-ejfv
Sacituzumab Govitecan
Others

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, 2018 - 2031

3.1. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Low-grade Bladder Cancer
3.1.1.2. High-grade Bladder Cancer
3.2. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Immunotherapy
3.2.1.1.1. Bacillus Calmette-Guerin
3.2.1.1.2. Avelumab
3.2.1.1.3. Nivolumab
3.2.1.1.4. Pembrolizumab
3.2.1.1.5. Others
3.2.1.2. Chemotherapy
3.2.1.2.1. Mitomycin C
3.2.1.2.2. Docetaxel
3.2.1.2.3. Paclitaxel
3.2.1.2.4. Cisplatin
3.2.1.2.5. Others
3.2.1.3. Targeted Therapy
3.2.1.3.1. Erdafitinib
3.2.1.3.2. Enfortumab Vedotin-ejfv
3.2.1.3.3. Sacituzumab Govitecan
3.2.1.3.4. Others
3.3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Specialty Pharmacies
3.3.1.4. Online Pharmacies
3.4. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, 2018 - 2031

4.1. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Low-grade Bladder Cancer
4.1.1.2. High-grade Bladder Cancer
4.2. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Immunotherapy
4.2.1.1.1. Bacillus Calmette-Guerin
4.2.1.1.2. Avelumab
4.2.1.1.3. Nivolumab
4.2.1.1.4. Pembrolizumab
4.2.1.1.5. Others
4.2.1.2. Chemotherapy
4.2.1.2.1. Mitomycin C
4.2.1.2.2. Docetaxel
4.2.1.2.3. Paclitaxel
4.2.1.2.4. Cisplatin
4.2.1.2.5. Others
4.2.1.3. Targeted Therapy
4.2.1.3.1. Erdafitinib
4.2.1.3.2. Enfortumab Vedotin-ejfv
4.2.1.3.3. Sacituzumab Govitecan
4.2.1.3.4. Others
4.3. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Specialty Pharmacies
4.3.1.4. Online Pharmacies
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, 2018 - 2031

5.1. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Low-grade Bladder Cancer
5.1.1.2. High-grade Bladder Cancer
5.2. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Immunotherapy
5.2.1.1.1. Bacillus Calmette-Guerin
5.2.1.1.2. Avelumab
5.2.1.1.3. Nivolumab
5.2.1.1.4. Pembrolizumab
5.2.1.1.5. Others
5.2.1.2. Chemotherapy
5.2.1.2.1. Mitomycin C
5.2.1.2.2. Docetaxel
5.2.1.2.3. Paclitaxel
5.2.1.2.4. Cisplatin
5.2.1.2.5. Others
5.2.1.3. Targeted Therapy
5.2.1.3.1. Erdafitinib
5.2.1.3.2. Enfortumab Vedotin-ejfv
5.2.1.3.3. Sacituzumab Govitecan
5.2.1.3.4. Others
5.3. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Specialty Pharmacies
5.3.1.4. Online Pharmacies
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, 2018 - 2031

6.1. Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Low-grade Bladder Cancer
6.1.1.2. High-grade Bladder Cancer
6.2. Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Immunotherapy
6.2.1.1.1. Bacillus Calmette-Guerin
6.2.1.1.2. Avelumab
6.2.1.1.3. Nivolumab
6.2.1.1.4. Pembrolizumab
6.2.1.1.5. Others
6.2.1.2. Chemotherapy
6.2.1.2.1. Mitomycin C
6.2.1.2.2. Docetaxel
6.2.1.2.3. Paclitaxel
6.2.1.2.4. Cisplatin
6.2.1.2.5. Others
6.2.1.3. Targeted Therapy
6.2.1.3.1. Erdafitinib
6.2.1.3.2. Enfortumab Vedotin-ejfv
6.2.1.3.3. Sacituzumab Govitecan
6.2.1.3.4. Others
6.3. Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Specialty Pharmacies
6.3.1.4. Online Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, 2018 - 2031

7.1. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Low-grade Bladder Cancer
7.1.1.2. High-grade Bladder Cancer
7.2. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
7.2.1.1. Immunotherapy
7.2.1.1.1. Bacillus Calmette-Guerin
7.2.1.1.2. Avelumab
7.2.1.1.3. Nivolumab
7.2.1.1.4. Pembrolizumab
7.2.1.1.5. Others
7.2.1.2. Chemotherapy
7.2.1.2.1. Mitomycin C
7.2.1.2.2. Docetaxel
7.2.1.2.3. Paclitaxel
7.2.1.2.4. Cisplatin
7.2.1.2.5. Others
7.2.1.3. Targeted Therapy
7.2.1.3.1. Erdafitinib
7.2.1.3.2. Enfortumab Vedotin-ejfv
7.2.1.3.3. Sacituzumab Govitecan
7.2.1.3.4. Others
7.3. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Specialty Pharmacies
7.3.1.4. Online Pharmacies
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, 2018 - 2031

8.1. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Low-grade Bladder Cancer
8.1.1.2. High-grade Bladder Cancer
8.2. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Immunotherapy
8.2.1.1.1. Bacillus Calmette-Guerin
8.2.1.1.2. Avelumab
8.2.1.1.3. Nivolumab
8.2.1.1.4. Pembrolizumab
8.2.1.1.5. Others
8.2.1.2. Chemotherapy
8.2.1.2.1. Mitomycin C
8.2.1.2.2. Docetaxel
8.2.1.2.3. Paclitaxel
8.2.1.2.4. Cisplatin
8.2.1.2.5. Others
8.2.1.3. Targeted Therapy
8.2.1.3.1. Erdafitinib
8.2.1.3.2. Enfortumab Vedotin-ejfv
8.2.1.3.3. Sacituzumab Govitecan
8.2.1.3.4. Others
8.3. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Specialty Pharmacies
8.3.1.4. Online Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market by Drug Type, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs Indication Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Merck KGaA
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Merck & Co.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. AstraZeneca PLC
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Roche Holding AG (Genentech)
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Astellas Pharma Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. J&J (Janssen Biotech)
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Cipla Inc.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Amneal Pharma
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Bristol Myers Squibb Co.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Dr. Reddy’s Laboratories, Inc.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Gilead Sciences Inc.
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Endo Pharma
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Pfizer Inc.
Novartis AG
Mylan N.V.
Teva Pharmaceuticals
Merck & Co.
Eli Lilly & Company
AstraZeneca PLC
Lupin Limited
Dr. Reddys Laboratories
Aurobindo Pharma Ltd.
GSK PLC
Sun Pharmaceutical Industries Ltd.

Methodology

LOADING...

Factors Driving the Non-Muscle Invasive Bladder Cancer Therapeutics Market

Contributing Factors to High Demand for NMIBC Therapies

Challenges Hindering Market Growth

Country-wise Insights

Category-wise Insights

Competitive Analysis

Key Segments of Non-muscle Invasive Bladder Cancer Therapeutics Industry

Cancer Grade:

Drug Type:

Distribution Channel:

Region:

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Bladder Cancer Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Muscle-invasive Bladder Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insight, Epidemiology And Market Forecast - 2034

Bladder Cancer Drugs Global Market Report 2024

Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034